Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model

S E Campbell; D Bennett; L Nasir; E A Gault; D J Argyle

doi:10.1093/rheumatology/keh590

Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model

S E Campbell, D Bennett, L Nasir, E A Gault, D J Argyle

Royal (Dick) School of Veterinary Studies

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The potential for undesirable systemic effects related to constitutive expression of certain therapeutic transgenes may be limited through the development of transcriptionally targeted disease- and cell-type-specific vectors. The objective of this study was to analyse the canine matrix metalloproteinase-9 (MMP-9) promoter and deletion constructs for its ability to drive expression in response to pro-inflammatory cytokines (interleukin-1beta and tumour necrosis factor-alpha).

Original language	English
Pages (from-to)	735-43
Number of pages	9
Journal	Rheumatology
Volume	44
Issue number	6
DOIs	https://doi.org/10.1093/rheumatology/keh590
Publication status	Published - Jun 2005

Keywords / Materials (for Non-textual outputs)

Animals
Base Sequence
Cell Line, Tumor
Collagen Type XI
Disease Models, Animal
Dogs
Gene Deletion
Genetic Therapy
Genetic Vectors
High Mobility Group Proteins
Interleukin-1
Introns
Matrix Metalloproteinase 9
Mice
Mutation
NF-kappa B
Osteoarthritis
Promoter Regions, Genetic
SOX9 Transcription Factor
Transcription Factors
Transcription, Genetic
Tumor Necrosis Factor-alpha

Access to Document

10.1093/rheumatology/keh590

Cite this

@article{764e6837805344a0b298e38f24755e80,

title = "Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model",

abstract = "The potential for undesirable systemic effects related to constitutive expression of certain therapeutic transgenes may be limited through the development of transcriptionally targeted disease- and cell-type-specific vectors. The objective of this study was to analyse the canine matrix metalloproteinase-9 (MMP-9) promoter and deletion constructs for its ability to drive expression in response to pro-inflammatory cytokines (interleukin-1beta and tumour necrosis factor-alpha).",

keywords = "Animals, Base Sequence, Cell Line, Tumor, Collagen Type XI, Disease Models, Animal, Dogs, Gene Deletion, Genetic Therapy, Genetic Vectors, High Mobility Group Proteins, Interleukin-1, Introns, Matrix Metalloproteinase 9, Mice, Mutation, NF-kappa B, Osteoarthritis, Promoter Regions, Genetic, SOX9 Transcription Factor, Transcription Factors, Transcription, Genetic, Tumor Necrosis Factor-alpha",

author = "Campbell, {S E} and D Bennett and L Nasir and Gault, {E A} and Argyle, {D J}",

year = "2005",

month = jun,

doi = "10.1093/rheumatology/keh590",

language = "English",

volume = "44",

pages = "735--43",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy

T2 - further development of a clinical canine model

AU - Campbell, S E

AU - Bennett, D

AU - Nasir, L

AU - Gault, E A

AU - Argyle, D J

PY - 2005/6

Y1 - 2005/6

N2 - The potential for undesirable systemic effects related to constitutive expression of certain therapeutic transgenes may be limited through the development of transcriptionally targeted disease- and cell-type-specific vectors. The objective of this study was to analyse the canine matrix metalloproteinase-9 (MMP-9) promoter and deletion constructs for its ability to drive expression in response to pro-inflammatory cytokines (interleukin-1beta and tumour necrosis factor-alpha).

AB - The potential for undesirable systemic effects related to constitutive expression of certain therapeutic transgenes may be limited through the development of transcriptionally targeted disease- and cell-type-specific vectors. The objective of this study was to analyse the canine matrix metalloproteinase-9 (MMP-9) promoter and deletion constructs for its ability to drive expression in response to pro-inflammatory cytokines (interleukin-1beta and tumour necrosis factor-alpha).

KW - Animals

KW - Base Sequence

KW - Cell Line, Tumor

KW - Collagen Type XI

KW - Disease Models, Animal

KW - Dogs

KW - Gene Deletion

KW - Genetic Therapy

KW - Genetic Vectors

KW - High Mobility Group Proteins

KW - Interleukin-1

KW - Introns

KW - Matrix Metalloproteinase 9

KW - Mice

KW - Mutation

KW - NF-kappa B

KW - Osteoarthritis

KW - Promoter Regions, Genetic

KW - SOX9 Transcription Factor

KW - Transcription Factors

KW - Transcription, Genetic

KW - Tumor Necrosis Factor-alpha

U2 - 10.1093/rheumatology/keh590

DO - 10.1093/rheumatology/keh590

M3 - Article

C2 - 15757961

SN - 1462-0324

VL - 44

SP - 735

EP - 743

JO - Rheumatology

JF - Rheumatology

IS - 6

ER -

Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this